Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03550794 · ClinicalTrials.gov registry record · Phase 2
Thiamine as a Renal Protective Agent in Septic Shock
A Phase 2 study of Sepsis and Kidney Injury, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 4
- Study locations
NCT03550794: Completed Phase 2 study of Sepsis and Kidney Injury, sponsored by Beth Israel Deaconess Medical Center.
NCT03550794 is a Phase 2 study of Sepsis and Kidney Injury that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 95 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03550794, a Phase 2 study of Sepsis and Kidney Injury, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.
Primary Outcome
Change in creatinine over time
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Thiamine Hydrochloride
Study Locations (4)
New York
- Northshore University Hospital - Manhasset
- Montefiore Medical Center - New York
- Long Island Jewish Hospital - Queens
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 2 |
What the finished NCT03550794 record still lists
NCT03550794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03550794 reports a single indexed study location in New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03550794 about?
NCT03550794 is a clinical study titled "Thiamine as a Renal Protective Agent in Septic Shock". This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.
What is the current status of trial NCT03550794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2018-09-04. Estimated completion is 2022-04-05.
What conditions does trial NCT03550794 study?
This clinical trial studies the following conditions: Sepsis, Kidney Injury, Thiamine Deficiency.
What interventions are being tested in trial NCT03550794?
The interventions under investigation include: Placebo (DRUG), Thiamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03550794?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03550794 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03550794's enrollment target sits among peer trials
95 57th of 90 higher than 34 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
-
An Acupuncture Study for People At High Risk for Sepsis
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI